异基因造血细胞移植后的新型复合终点。
Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.
机构信息
Department of Data Science, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts.
Center for International Blood and Marrow Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
出版信息
Transplant Cell Ther. 2021 Aug;27(8):650-657. doi: 10.1016/j.jtct.2021.05.005. Epub 2021 May 15.
Abstract
With the recent development of transplant-specific composite endpoints for evaluation of allogeneic hematopoietic cell transplantation (alloHCT) outcomes, the use of these novel endpoints is growing rapidly. Combining multiple endpoints into a single endpoint, these composite endpoints appear simple and can be used as a summary measure for overall effectiveness of an intervention. However, all component endpoints may not have equal clinical significance, and an intervention may not work proportionally in the same direction for all components of a composite endpoint. This may complicate the interpretation of results, particularly if there are opposing effects of differing component endpoints. We assess the benefits and limitations of various composite endpoints used in alloHCT studies recently and propose guidelines for their use and interpretation. © 2021 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
摘要
随着用于评估异基因造血细胞移植 (alloHCT) 结果的移植特异性综合终点的最新发展，这些新终点的使用正在迅速增加。这些综合终点将多个终点结合到一个单一终点中，看起来很简单，可以作为干预措施总体有效性的综合衡量标准。然而，并非所有的终点都具有同等的临床意义，而且干预措施可能不会以相同的比例在综合终点的所有组成部分中发挥作用。如果不同组成部分的终点有相反的效果，这可能会使结果的解释变得复杂。我们评估了最近 alloHCT 研究中使用的各种综合终点的优缺点，并提出了使用和解释这些终点的指南。
2021 年美国血液和骨髓移植学会。版权所有。
相似文献
1
Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后的新型复合终点。
Transplant Cell Ther. 2021 Aug;27(8):650-657. doi: 10.1016/j.jtct.2021.05.005. Epub 2021 May 15.
2
Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.供者类型和疾病风险预测异基因造血细胞移植的成功：采用改良复合终点对 613 例成人造血细胞移植受者的单中心分析。
Biol Blood Marrow Transplant. 2017 Dec;23(12):2192-2198. doi: 10.1016/j.bbmt.2017.08.030. Epub 2017 Aug 30.
3
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.异基因造血干细胞移植后髓源性抑制细胞的早期恢复：环磷酰胺与标准移植物抗宿主病预防的比较。
Transplant Cell Ther. 2022 Apr;28(4):203.e1-203.e7. doi: 10.1016/j.jtct.2021.12.019. Epub 2022 Jan 5.
4
Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.评估异基因移植后急性移植物抗宿主病的个体与复合终点对长期生存的影响。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1682-1688. doi: 10.1016/j.bbmt.2019.01.024. Epub 2019 Jan 30.
5
Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.异基因造血干细胞移植前老年人药物滥用的影响。
Transplant Cell Ther. 2021 Apr;27(4):344.e1-344.e5. doi: 10.1016/j.jtct.2021.01.001. Epub 2021 Jan 7.
6
Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.低剂量抗胸腺细胞球蛋白预防亲缘全相合异基因造血干细胞移植后移植物抗宿主病
Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15.
7
The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.供体类型对儿童白血病异基因造血细胞移植结局和成本的影响：国际血液和骨髓移植研究中心与儿科健康信息系统合并分析
Biol Blood Marrow Transplant. 2020 Sep;26(9):1747-1756. doi: 10.1016/j.bbmt.2020.05.016. Epub 2020 May 25.
8
Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.预测复发或难治性非霍奇金淋巴瘤患者接受异基因造血干细胞移植后移植物抗宿主病和无复发生存的风险因素。
Ann Hematol. 2019 Jul;98(7):1743-1753. doi: 10.1007/s00277-019-03714-x. Epub 2019 May 14.
9
The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.高级患者年龄对非霍奇金淋巴瘤异基因造血细胞移植后死亡率的影响：欧洲血液和骨髓移植协会淋巴瘤工作组的回顾性研究。
Biol Blood Marrow Transplant. 2019 Jan;25(1):86-93. doi: 10.1016/j.bbmt.2018.08.025. Epub 2018 Sep 13.
10
Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.部分T细胞清除可改善异基因造血干细胞移植后无移植物抗宿主病、无复发的复合终点生存率。
Leuk Lymphoma. 2018 Mar;59(3):590-600. doi: 10.1080/10428194.2017.1344844. Epub 2017 Jul 6.
引用本文的文献
1
Impact of payment source, referral site, and place of residence on outcomes after allogeneic transplantation in Mexico.支付来源、转诊地点及居住地址对墨西哥异基因移植术后结局的影响
World J Transplant. 2024 Jun 18;14(2):91052. doi: 10.5500/wjt.v14.i2.91052.
2
Competing risks data in clinical oncology.临床肿瘤学中的竞争风险数据。
Front Oncol. 2024 Apr 4;14:1360266. doi: 10.3389/fonc.2024.1360266. eCollection 2024.
3
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.无进展生存期、无疾病生存期和其他肿瘤学复合终点：需要改进报告。
Nat Rev Clin Oncol. 2023 Dec;20(12):885-895. doi: 10.1038/s41571-023-00823-5. Epub 2023 Oct 12.
4
Endpoint selection and evaluation in hematology studies.终点选择和评估在血液学研究中的应用。
Best Pract Res Clin Haematol. 2023 Sep;36(3):101479. doi: 10.1016/j.beha.2023.101479. Epub 2023 May 24.
5
Designing and conducting a clinical trial in blood and marrow transplantation.设计和开展血液和骨髓移植临床试验。
Best Pract Res Clin Haematol. 2023 Jun;36(2):101471. doi: 10.1016/j.beha.2023.101471. Epub 2023 May 11.
6
Inferences for current chronic graft-versus-host-disease free and relapse free survival.当前慢性移植物抗宿主病无病和无复发生存的推断。
BMC Med Res Methodol. 2022 Dec 13;22(1):318. doi: 10.1186/s12874-022-01771-x.
本文引用的文献
1
Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.优化异基因造血细胞移植中的供体选择和移植物抗宿主病预防
J Clin Oncol. 2021 Feb 10;39(5):373-385. doi: 10.1200/JCO.20.01771. Epub 2021 Jan 12.
2
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.成人供体异基因造血干细胞移植后复合 GRFS 和 CRFS 结局
J Clin Oncol. 2020 Jun 20;38(18):2062-2076. doi: 10.1200/JCO.19.00396. Epub 2020 May 4.
3
Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.动态移植物抗宿主病无复发生存：同种异体移植发病率和死亡率的多状态建模。
Biol Blood Marrow Transplant. 2019 Sep;25(9):1884-1889. doi: 10.1016/j.bbmt.2019.05.015. Epub 2019 May 22.
4
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).三种预防方案（他克莫司、霉酚酸酯和环磷酰胺；他克莫司、甲氨蝶呤和硼替佐米；或他克莫司、甲氨蝶呤和马拉维若）与他克莫司和甲氨蝶呤用于预防低强度预处理造血细胞移植后的移植物抗宿主病：一项带有非随机同期对照组的随机2期试验（BMT CTN 1203）
Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.
5
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.移植物抗白血病效应对急性淋巴细胞白血病患者生存的影响。
Blood Adv. 2019 Feb 26;3(4):670-680. doi: 10.1182/bloodadvances.2018027003.
6
Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.评估异基因移植后急性移植物抗宿主病的个体与复合终点对长期生存的影响。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1682-1688. doi: 10.1016/j.bbmt.2019.01.024. Epub 2019 Jan 30.
7
Understanding the Use of Composite Endpoints in Clinical Trials.理解临床试验中复合终点的应用。
West J Emerg Med. 2018 Jul;19(4):631-634. doi: 10.5811/westjem.2018.4.38383. Epub 2018 Jun 4.
8
Patient-reported outcomes and health status associated with chronic graft--host disease.与慢性移植物抗宿主病相关的患者报告结局和健康状况。
Haematologica. 2018 Sep;103(9):1535-1541. doi: 10.3324/haematol.2018.192930. Epub 2018 Jun 1.
9
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.抗T淋巴细胞球蛋白用于评估对接受HLA匹配的非血缘清髓性造血细胞移植患者慢性移植物抗宿主病无病生存影响的前瞻性、随机、双盲、III期临床试验。
J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.
10
Composite and multicomponent end points in clinical trials.临床试验中的复合和多组分终点
Stat Med. 2017 Dec 10;36(28):4437-4440. doi: 10.1002/sim.7386. Epub 2017 Jul 4.
Zotero 插件